Tag: inhalation cdmo market opportunities

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Inhalation CDMO Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The inhalation CDMO market has experienced robust expansion in recent years. This sector is projected to grow from $2.2 billion in 2025 to $2.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.4%. The historical increase in the market size can be attributed to factors such as the rising prevalence of asthma and COPD, an increasing demand for inhalation therapies, the growth of biologics and specialized drug formulations, advancements in formulation technologies, and the increasing outsourcing by pharmaceutical companies.

The inhalation cdmo market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $3.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected increase during the forecast timeframe stems from factors such as the broadening use of digital and smart inhalers, the progression of personalized medicine and precision therapy, enhanced capital expenditure in inhalation cdmo infrastructure, the growing implementation of advanced manufacturing techniques, and a rise in partnerships between biotechnology companies and CDMOs. Key developments expected within this period encompass the evolution of personalized inhalation therapies, sophisticated formulation and drug delivery methodologies, improved regulatory adherence and quality assurance measures, the growth of contract manufacturing services for small and medium enterprises, and the incorporation of smart inhalers with digital health monitoring systems.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=45955921&type=smp&name=Inhalation%20CDMO%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Inhalation CDMO Market Growth Factors: What’s Supporting Expansion?

The inhalation CDMO market is anticipated to expand due to the rising occurrence of respiratory conditions. These disorders encompass various medical issues impacting the respiratory system, which comprises the organs and structures essential for breathing. Inhalation CDMOs play a crucial role in developing and manufacturing products for respiratory ailments, leveraging their proficiency in drug formulation and delivery to the lungs. They provide pharmaceutical firms with specialized knowledge, facilities, and assets necessary for introducing innovative inhalation treatments. For example, data from December 2023, released by the National Library of Medicine, a US-based medical library, indicates that worldwide chronic obstructive pulmonary disease (COPD) cases among individuals 25 and older are forecast to increase by 23% by 2050, totaling almost 600 million. Consequently, the growing frequency of respiratory disorders is fueling the expansion of the inhalation CDMO market.

Inhalation CDMO Market Segment Analysis And Revenue Potential

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

Inhalation CDMO Market Industry Trends: What’s Reshaping Demand?

Leading companies operating in the inhalation CDMO industry are increasingly adopting a strategic partnership approach to provide specialized drug development and delivery services. Such a partnership constitutes a long-term, mutually beneficial arrangement between two or more organizations working together to achieve shared objectives. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, collaborated with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This alliance is centered on creating new technologies designed to deliver higher drug doses and improve the efficiency of drug delivery to the lungs.

Inhalation CDMO Market Key Players Shaping Industry Direction

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

View The Full Inhalation CDMO Market Report:

https://thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Inhalation CDMO Market Leading Geography: Which Region Contributes The Most Revenue?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Inhalation CDMO Market Value Expansion And Long-Term Growth Outlook

The inhalation CDMO market has experienced robust expansion in recent years. Its value is projected to increase from $2.2 billion in 2025 to $2.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.4%. The historic growth is driven by factors such as the growing incidence of asthma and chronic obstructive pulmonary disease (COPD), a rising need for inhalation-based treatments, the emergence of biologics and specialized drug formulations, progress in formulation technologies, and a heightened reliance on outsourcing by pharmaceutical firms.

The inhalation CDMO market is forecast to undergo significant expansion over the next several years, with projections indicating it will reach $3.03 billion by 2030, reflecting a compound annual growth rate of 6.6%. This anticipated increase during the forecast period is driven by several key factors, including the widespread adoption of digital and smart inhalers, advances in personalized medicine and precision therapy, greater financial commitment to inhalation CDMO infrastructure, broader implementation of cutting-edge manufacturing technologies, and a higher frequency of collaborations between biotech firms and CDMOs. Notable trends expected to shape this period involve the development of customized inhalation therapies, novel formulation methods and drug delivery technologies, improvements in regulatory compliance and quality assurance, the growth of contract manufacturing capabilities tailored for small and medium-sized enterprises, and the convergence of smart inhaler technology with digital health monitoring systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Inhalation CDMO Market Growth Momentum: Which Factors Are Influencing Demand?

The anticipated growth of the inhalation CDMO market is being driven by the rising incidence of respiratory disorders. These conditions encompass a range of medical issues affecting the respiratory system, including the organs and structures necessary for breathing. Inhalation CDMOs play a key role in developing and manufacturing products for such disorders, leveraging their specialized knowledge in formulating and delivering drugs to the lungs, while providing pharmaceutical companies with the expertise, infrastructure, and resources needed to advance innovative inhalation therapies. For example, in December 2023, the National Library of Medicine, a US-based medical library, reported that the global number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is expected to increase by 23% by 2050, reaching nearly 600 million. Consequently, the growing prevalence of respiratory disorders is fueling the expansion of the inhalation CDMO market.

Inhalation CDMO Market Categorization By Product Type And Application

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

Inhalation CDMO Market Trends Reshaping Industry Growth

Leading firms within the inhalation CDMO sector are increasingly utilizing strategic alliances to deliver specialized capabilities in drug development and delivery. A strategic alliance represents a long-term, cooperative relationship between organizations that collaborates to accomplish mutual objectives. For example, in May 2023, Hovione, a contract development and manufacturing organization based in Portugal, formed a collaboration with H&T Presspart, a UK-based producer of high-precision pharmaceutical metal and plastic components, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler system. This collaboration is aimed at creating novel technologies that enable higher drug dosages and enhance the effectiveness of lung drug delivery.

Inhalation CDMO Market Company Landscape And Strategic Competition

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

Access The Complete Inhalation CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Inhalation CDMO Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Inhalation CDMO Market Increase Between 2026 And 2030?

The inhalation CDMO market has experienced substantial growth in recent years. This market is projected to expand from $2.2 billion in 2025 to $2.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.4%. Historically, this growth can be attributed to the rising prevalence of asthma and COPD, an increasing demand for inhalation therapies, the growth of biologics and specialized drug formulations, continuous advancements in formulation technologies, and the growing trend of outsourcing by pharmaceutical companies.

The inhalation cdmo market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $3.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast timeframe can be ascribed to several factors, including the proliferation of digital and smart inhalers, the rise of personalized medicine and precision therapy, heightened investment in inhalation cdmo infrastructure, the growing uptake of advanced manufacturing technologies, and increased partnerships between biotechnology companies and CDMOs. Key trends anticipated during the forecast period encompass the advancement of personalized inhalation therapies, sophisticated formulation and drug delivery methodologies, improvements in regulatory adherence and quality assurance, the broadening of contract manufacturing services for small and medium-sized enterprises, and the integration of smart inhalers with digital health monitoring systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

What Core Drivers Are Transforming The Inhalation CDMO Market?

The escalating occurrence of respiratory ailments is anticipated to drive the expansion of the inhalation CDMO market in the future. These disorders encompass various medical conditions impacting the respiratory system, comprising the organs and structures crucial for respiration. Inhalation CDMOs play a crucial role in creating and producing treatments for respiratory conditions, leveraging their proficiency in drug formulation and lung delivery. They provide specialized knowledge, facilities, and assets to pharmaceutical firms aiming to introduce novel inhalation therapies. For example, data from December 2023, sourced from the US-based medical library, the National Library of Medicine, indicates that the worldwide incidence of chronic obstructive pulmonary disease (COPD) among individuals aged 25 and older is predicted to increase by 23% by 2050, potentially affecting nearly 600 million people. Consequently, the rising occurrence of respiratory conditions is fueling the expansion of the inhalation CDMO market.

What Key Segment Areas Are Included In The Inhalation CDMO Market Assessment?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

Which Trends Are Affecting The Inhalation CDMO Market Framework?

Major corporations within the inhalation CDMO industry are increasingly adopting a strategic partnership approach to deliver specialized drug development and delivery services. A strategic partnership is defined as a long-term, mutually beneficial agreement between two or more entities working together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, formed a partnership with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, with the goal of developing Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This collaboration is specifically focused on advancing new technologies that can facilitate the delivery of higher drug doses and enhance the efficiency of drug delivery to the lungs.

Which Organizations Are Operating Within The Inhalation CDMO Market?

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

Access The Complete Inhalation CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Region Has The Strongest Presence In The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Inhalation CDMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2026, By The Business Research Company

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Inhalation CDMO Market During The Forecast Period?

The inhalation cdmo market size has seen substantial growth in recent years. It is anticipated to increase from $2.2 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. This historical expansion can be attributed to several factors, including the increasing prevalence of asthma and copd, a heightened demand for inhalation therapies, the development of biologics and specialized drug formulations, continuous advancements in formulation technologies, and the rising trend of outsourcing by pharmaceutical companies.

The inhalation cdmo market is projected to experience significant expansion in the coming years, with its size expected to reach $3.03 billion in 2030, growing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth throughout the forecast period is primarily driven by the proliferation of digital and smart inhalers, advancements in personalized medicine and precision therapy, increased capital expenditure in inhalation cdmo infrastructure, the growing adoption of sophisticated manufacturing technologies, and a rise in strategic partnerships between biotech companies and CDMOs. Prominent trends for the forecast period include the development of personalized inhalation therapies, the application of advanced formulation and drug delivery techniques, enhancements in regulatory compliance and quality assurance standards, an expansion of contract manufacturing services for small and medium-sized enterprises, and the integration of smart inhalers with digital health monitoring systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

What Key Factors Are Affecting The Inhalation CDMO Market Demand?

The rising occurrence of respiratory illnesses is anticipated to fuel the expansion of the inhalation CDMO market in the future. These disorders encompass various medical conditions impacting the respiratory system, specifically the organs and structures essential for respiration. Inhalation CDMOs play a crucial role in creating and producing treatments for respiratory ailments, leveraging their proficiency in drug formulation and delivery to the lungs, and offering specialized expertise, infrastructure, and resources to pharmaceutical firms developing advanced inhalation therapies. For example, data from the National Library of Medicine, a US-based medical library, revealed in December 2023 that the worldwide incidence of chronic obstructive pulmonary disease (COPD) in individuals aged 25 and above is forecast to increase by 23% by 2050, potentially affecting almost 600 million people. Consequently, the growing frequency of respiratory conditions is propelling the development of the inhalation CDMO market.

How Is The Inhalation CDMO Market Broken Down By Segment Categories?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

What Emerging Trends Are Seen In The Inhalation CDMO Market?

Leading companies within the inhalation CDMO sector are increasingly forming strategic alliances to deliver specialized drug development and delivery solutions. A strategic partnership denotes a long-standing, mutually beneficial arrangement between two or more entities collaborating to achieve common objectives. As an example, in May 2023, Hovione, a Contract Development and Manufacturing Organization situated in Portugal, joined forces with H&T Presspart, a UK-based producer of high-precision metal and plastic components for the pharmaceutical industry, to progress Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This collaboration aims to innovate new technologies that facilitate the delivery of higher drug doses and enhance the efficiency of drug administration to the lungs.

Which Players Are Present In The Inhalation CDMO Market Space?

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

Get The Full Inhalation CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Region Is The Leading Market For The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Inhalation CDMO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2026, By The Business Research Company

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Inhalation CDMO Market Between 2026 And 2030?

The inhalation cdmo market size has experienced strong growth in recent years. It is anticipated to increase from $2.2 billion in 2025 to $2.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.4%. The expansion observed historically can be linked to the rising prevalence of asthma and copd, a growing demand for inhalation therapies, the development of biologics and specialized drug formulations, progress in formulation technologies, and an increase in outsourcing by pharmaceutical companies.

The inhalation cdmo market size is anticipated to undergo significant expansion in the upcoming years. Its value is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.6%. This expected growth is primarily fueled by the increasing prevalence of digital and smart inhalers, the evolution of personalized medicine and precision therapy, heightened investment in inhalation cdmo infrastructure, the growing adoption of advanced manufacturing technologies, and a rise in collaborations between biotech firms and cdmos. Prominent trends for this forecast period involve the development of personalized inhalation therapies, sophisticated formulation and drug delivery techniques, enhancements in regulatory compliance and quality assurance, the widening of contract manufacturing opportunities for small and medium-sized businesses, and the integration of smart inhalers with digital health monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

What Major Drivers Are Influencing Demand In The Inhalation CDMO Market?

A growing occurrence of respiratory disorders is anticipated to stimulate the expansion of the inhalation CDMO market moving forward. Respiratory disorders are a collection of medical conditions that impact the respiratory system, encompassing the organs and structures involved in breathing. Inhalation CDMOs are utilized in the development and manufacturing of products designed for respiratory disorders, owing to their specialized knowledge in formulating and delivering drugs to the lungs, and offering dedicated expertise, infrastructure, and resources to pharmaceutical companies seeking to introduce innovative inhalation therapies. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the global number of chronic obstructive pulmonary disease (COPD) cases among those 25 and older is projected to rise by 23% by 2050, reaching nearly 600 million. Consequently, the increasing prevalence of respiratory disorders is fueling the growth of the inhalation CDMO market.

Which Market Segments Are Examined In The Inhalation CDMO Market Study?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

Which Trends Are Influencing The Inhalation CDMO Market?

Leading companies in the inhalation CDMO industry are increasingly forming strategic partnerships to deliver specialized drug development and delivery solutions. A strategic partnership involves a long-term, mutually beneficial agreement between two or more firms collaborating to achieve common objectives. For instance, in May 2023, Hovione, a Contract Development and Manufacturing Organization based in Portugal, entered into a partnership with H&T Presspart, a UK-based producer of high-precision metal and plastic components for the pharmaceutical sector, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This collaboration aims to develop new technologies that can administer higher drug doses and enhance the efficiency of drug delivery to the lungs.

Who Are The Primary Competitors In The Inhalation CDMO Market?

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

Read the full inhalation cdmo market report here:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Inhalation CDMO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2026, By The Business Research Company

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the inhalation cdmo market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Inhalation CDMO Market?

The inhalation cdmo market size has shown substantial growth in recent years. It is anticipated to increase from $2.2 billion in 2025 to $2.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The expansion observed historically can be attributed to factors such as the increasing prevalence of asthma and copd, a heightened demand for inhalation therapies, the development of biologics and specialized drug formulations, ongoing advancements in formulation technologies, and the rising practice of outsourcing among pharmaceutical companies.

The inhalation cdmo market is anticipated to experience substantial growth over the coming years, with projections indicating it will reach $3.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expected expansion is primarily driven by factors such as the increasing availability of digital and smart inhalers, the progression of personalized medicine and precision therapies, heightened investment in inhalation cdmo infrastructure, the growing adoption of sophisticated manufacturing technologies, and a surge in collaborations between biotech companies and CDMOs. Significant trends for the forecast period include the development of personalized inhalation therapies, advancements in formulation and drug delivery techniques, strengthened regulatory compliance and quality assurance, the expansion of contract manufacturing for small and medium-sized enterprises, and the integration of smart inhalers with digital health monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

What Drivers Are Supporting Technological Adoption In The Inhalation CDMO Market?

The expanding occurrence of respiratory conditions is anticipated to stimulate the future growth of the inhalation CDMO market. Respiratory disorders encompass a range of medical issues impacting the respiratory system, which includes the organs and structures essential for breathing. Inhalation CDMOs are vital in the development and manufacturing of products designed for respiratory disorders, thanks to their expertise in formulating and delivering drugs directly to the lungs. They offer specialized knowledge, infrastructure, and resources to pharmaceutical companies aiming to launch innovative inhalation therapies. For instance, in December 2023, information from the National Library of Medicine, a US-based medical library, stated that the worldwide count of chronic obstructive pulmonary disease (COPD) cases among individuals 25 and older is forecast to surge by 23% by 2050, reaching nearly 600 million. This increasing prevalence of respiratory disorders is therefore a significant factor propelling the expansion of the inhalation CDMO market.

What Segment Types Are Examined In The Inhalation CDMO Market?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

What Long-Term Trends Are Expected To Shape The Future Of The Inhalation CDMO Market?

Leading firms within the inhalation Contract Development and Manufacturing Organization sector are implementing a strategic collaboration strategy to offer expert drug formulation and administration services. Such a partnership involves an enduring, advantageous agreement between multiple entities cooperating towards common objectives. As an illustration, in May of 2023, Hovione, a CDMO based in Portugal, collaborated with H&T Presspart, a UK manufacturer of precise metal and plastic components for pharmaceuticals, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This joint effort aims at creating innovative technologies capable of providing increased drug dosages and enhancing the effectiveness of medication delivery into the lungs.

Who Are The Primary Competitors In The Global Inhalation CDMO Market?

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Inhalation CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2026, By The Business Research Company

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the inhalation cdmo market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Inhalation CDMO Market And What Value Is Projected For 2029?

The inhalation CDMO market size has shown robust growth recently. It is anticipated to expand from $2.08 billion in 2024 to $2.2 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.0%. The expansion observed historically is largely due to the rising prevalence of respiratory disorders, the growing demand for personalized medicine, increased outsourcing by pharmaceutical companies, and the overall growth of the biopharmaceutical industry.

The inhalation CDMO market size is anticipated to undergo significant expansion in the upcoming years, with projections indicating a rise to $2.84 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.5%. This growth throughout the forecast period is primarily driven by an emphasis on precision medicine and targeted therapies, the swift development of biopharmaceutical inhalation treatments, a dedication to patient-centric approaches, broader global market penetration and new opportunities in emerging markets, and supportive regulatory environments for the advancement of inhalation drugs. Prominent trends expected during this period encompass an escalating demand for digital health solutions, the proliferation of biologic inhalation therapies, a commitment to sustainable inhaler technologies, the integration of artificial intelligence (AI) and machine learning, and an increase in strategic collaborations and partnerships.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

What Factors Are Boosting The Inhalation CDMO Market?

The rising occurrence of respiratory ailments is anticipated to drive the expansion of the inhalation CDMO market in the future. Respiratory disorders are medical conditions that impact the respiratory system, including the organs and structures essential for breathing. Inhalation CDMOs are instrumental in the development and manufacturing of products for these conditions, leveraging their expertise in formulating and delivering drugs to the lungs. They provide specialized knowledge, infrastructure, and resources to pharmaceutical companies aiming to introduce innovative inhalation therapies. For instance, according to the Australian Bureau of Statistics (ABS), an Australia-based Government agency, 8.5 million Australians (34%) reported having chronic respiratory conditions, which included 2.8 million people (11%) with asthma and 638,000 people (2.5%) with COPD. Thus, the increasing prevalence of respiratory disorders is a significant force behind the growth of the inhalation CDMO market.

What Are The Core Segmentation Criteria In The Inhalation CDMO Market?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

Which Emerging Trends Are Reshaping The Inhalation CDMO Market Landscape?

Leading companies in the inhalation CDMO industry are increasingly utilizing a strategic partnership method to offer specialized drug development and delivery solutions. A strategic partnership signifies a long-standing, mutually advantageous arrangement between two or more firms collaborating to achieve shared objectives. For example, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, collaborated with H&T Presspart, a UK-based producer of high-precision metal and plastic components for the pharmaceutical sector, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This alliance is focused on creating innovative technologies that enable higher drug dose delivery and boost the efficiency of medication reaching the lungs.

Which Players Are Shaping The Competitive Landscape Of The Inhalation CDMOXX Market?

Major companies operating in the inhalation CDMO market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

What Regional Trends Are Shaping Growth In The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Cellulars Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Dermatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Inhalation CDMO Industry By The Forecast Year 2029?

The inhalation CDMO market has shown robust expansion over recent years. It is anticipated to expand further, reaching $2.2 billion in 2025 from $2.08 billion in 2024, exhibiting a compound annual growth rate (CAGR) of 6.0%. This growth in previous periods can be linked to factors such as the increasing incidence of respiratory conditions, the growing requirement for personalized healthcare, the rise in outsourcing activities by pharmaceutical firms, and the general advancement of the biopharmaceutical sector.

The inhalation CDMO market is projected to experience significant expansion in the upcoming years. This market is anticipated to reach $2.84 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the projection period include an emphasis on precision medicine and targeted treatments, the swift growth of biopharmaceutical inhalation therapies, a focus on patient-focused solutions, the expansion into global markets and new market prospects, and regulatory assistance for the development of inhalation drugs. Key trends expected during the forecast period encompass a rising need for digital health innovations, advancements in biologic inhalation therapies, a commitment to sustainable inhaler technologies, the incorporation of artificial intelligence (AI) and machine learning, and strategic alliances and collaborations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

Which Drivers Are Supporting Growth Of The Inhalation CDMO Market?

The rising occurrence of respiratory ailments is anticipated to drive the expansion of the inhalation CDMO market in the coming years. Respiratory disorders are a collection of medical conditions impacting the respiratory system, which comprises the organs and components essential for breathing. Inhalation CDMOs are instrumental in the creation and production of products for these disorders, leveraging their proficiency in developing and administering drugs directly to the lungs. They offer unique expertise, facilities, and resources to pharmaceutical companies aiming to introduce innovative inhalation treatments. For instance, data from the Australian Bureau of Statistics (ABS), an Australia-based Government agency, revealed that 8.5 million Australians (34%) reported having chronic respiratory conditions. This total included 2.8 million people (11%) with asthma and 638,000 people (2.5%) with COPD. Thus, the increasing prevalence of respiratory disorders is a significant force behind the growth of the inhalation CDMO market.

Which Key Segments Fueling The Inhalation CDMO Market?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

What Are The Latest Industry Trends Transforming The Inhalation CDMO Market?

Leading companies in the inhalation CDMO industry are adopting strategic partnerships to deliver specialized drug development and delivery solutions. A strategic partnership involves a long-term, mutually beneficial arrangement where two or more companies collaborate to achieve shared objectives. For instance, in May 2023, Hovione, a Contract Development and Manufacturing Organization from Portugal, formed a partnership with H&T Presspart, a UK-based producer of high-precision metal and plastic components for the pharmaceutical sector, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This collaboration aims to develop new technologies capable of delivering higher drug doses and improving the efficiency of drug delivery to the lungs.

Which Leading Companies Dominate The Inhalation CDMO Market Share?

Major companies operating in the inhalation CDMO market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Region Currently Holds The Largest Share Of The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Inhalation CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Cellulars Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Dermatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Inhalation CDMO Industry By The Forecast Year 2029?

The inhalation CDMO market has shown robust expansion over recent years. It is anticipated to expand further, reaching $2.2 billion in 2025 from $2.08 billion in 2024, exhibiting a compound annual growth rate (CAGR) of 6.0%. This growth in previous periods can be linked to factors such as the increasing incidence of respiratory conditions, the growing requirement for personalized healthcare, the rise in outsourcing activities by pharmaceutical firms, and the general advancement of the biopharmaceutical sector.

The inhalation CDMO market is projected to experience significant expansion in the upcoming years. This market is anticipated to reach $2.84 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the projection period include an emphasis on precision medicine and targeted treatments, the swift growth of biopharmaceutical inhalation therapies, a focus on patient-focused solutions, the expansion into global markets and new market prospects, and regulatory assistance for the development of inhalation drugs. Key trends expected during the forecast period encompass a rising need for digital health innovations, advancements in biologic inhalation therapies, a commitment to sustainable inhaler technologies, the incorporation of artificial intelligence (AI) and machine learning, and strategic alliances and collaborations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

Which Drivers Are Supporting Growth Of The Inhalation CDMO Market?

The rising occurrence of respiratory ailments is anticipated to drive the expansion of the inhalation CDMO market in the coming years. Respiratory disorders are a collection of medical conditions impacting the respiratory system, which comprises the organs and components essential for breathing. Inhalation CDMOs are instrumental in the creation and production of products for these disorders, leveraging their proficiency in developing and administering drugs directly to the lungs. They offer unique expertise, facilities, and resources to pharmaceutical companies aiming to introduce innovative inhalation treatments. For instance, data from the Australian Bureau of Statistics (ABS), an Australia-based Government agency, revealed that 8.5 million Australians (34%) reported having chronic respiratory conditions. This total included 2.8 million people (11%) with asthma and 638,000 people (2.5%) with COPD. Thus, the increasing prevalence of respiratory disorders is a significant force behind the growth of the inhalation CDMO market.

Which Key Segments Fueling The Inhalation CDMO Market?

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

What Are The Latest Industry Trends Transforming The Inhalation CDMO Market?

Leading companies in the inhalation CDMO industry are adopting strategic partnerships to deliver specialized drug development and delivery solutions. A strategic partnership involves a long-term, mutually beneficial arrangement where two or more companies collaborate to achieve shared objectives. For instance, in May 2023, Hovione, a Contract Development and Manufacturing Organization from Portugal, formed a partnership with H&T Presspart, a UK-based producer of high-precision metal and plastic components for the pharmaceutical sector, to advance Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This collaboration aims to develop new technologies capable of delivering higher drug doses and improving the efficiency of drug delivery to the lungs.

Which Leading Companies Dominate The Inhalation CDMO Market Share?

Major companies operating in the inhalation CDMO market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Region Currently Holds The Largest Share Of The Inhalation CDMO Market?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Inhalation CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Cellulars Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Dermatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model